These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26752302)

  • 21. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
    Brunelle MN; Jacquard AC; Pichoud C; Durantel D; Carrouée-Durantel S; Villeneuve JP; Trépo C; Zoulim F
    Hepatology; 2005 Jun; 41(6):1391-8. PubMed ID: 15915463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic suppression of dengue virus replication using a combination of nucleoside analogs and nucleoside synthesis inhibitors.
    Yeo KL; Chen YL; Xu HY; Dong H; Wang QY; Yokokawa F; Shi PY
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2086-93. PubMed ID: 25624323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.
    Okuse C; Rinaudo JA; Farrar K; Wells F; Korba BE
    Antiviral Res; 2005 Jan; 65(1):23-34. PubMed ID: 15652968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists.
    Cheng H; Lear-Rooney CM; Johansen L; Varhegyi E; Chen ZW; Olinger GG; Rong L
    J Virol; 2015 Oct; 89(19):9932-8. PubMed ID: 26202243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An RNA polymerase II-driven Ebola virus minigenome system as an advanced tool for antiviral drug screening.
    Nelson EV; Pacheco JR; Hume AJ; Cressey TN; Deflubé LR; Ruedas JB; Connor JH; Ebihara H; Mühlberger E
    Antiviral Res; 2017 Oct; 146():21-27. PubMed ID: 28807685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference.
    Geisbert TW; Hensley LE; Kagan E; Yu EZ; Geisbert JB; Daddario-DiCaprio K; Fritz EA; Jahrling PB; McClintock K; Phelps JR; Lee AC; Judge A; Jeffs LB; MacLachlan I
    J Infect Dis; 2006 Jun; 193(12):1650-7. PubMed ID: 16703508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
    Cooper DA; Heera J; Goodrich J; Tawadrous M; Saag M; Dejesus E; Clumeck N; Walmsley S; Ting N; Coakley E; Reeves JD; Reyes-Teran G; Westby M; Van Der Ryst E; Ive P; Mohapi L; Mingrone H; Horban A; Hackman F; Sullivan J; Mayer H
    J Infect Dis; 2010 Mar; 201(6):803-13. PubMed ID: 20151839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Synthetic Serine Protease Inhibitor, Nafamostat Mesilate, Is a Drug Potentially Applicable to the Treatment of Ebola Virus Disease.
    Nishimura H; Yamaya M
    Tohoku J Exp Med; 2015 Sep; 237(1):45-50. PubMed ID: 26346967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
    Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
    J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity.
    Johansen LM; DeWald LE; Shoemaker CJ; Hoffstrom BG; Lear-Rooney CM; Stossel A; Nelson E; Delos SE; Simmons JA; Grenier JM; Pierce LT; Pajouhesh H; Lehár J; Hensley LE; Glass PJ; White JM; Olinger GG
    Sci Transl Med; 2015 Jun; 7(290):290ra89. PubMed ID: 26041706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical discovery and development of maraviroc for the treatment of HIV.
    Veljkovic N; Vucicevic J; Tassini S; Glisic S; Veljkovic V; Radi M
    Expert Opin Drug Discov; 2015 Jun; 10(6):671-84. PubMed ID: 25927601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial.
    Konde MK; Baker DP; Traore FA; Sow MS; Camara A; Barry AA; Mara D; Barry A; Cone M; Kaba I; Richard AA; Beavogui AH; Günther S; ; Pintilie M; Fish EN
    PLoS One; 2017; 12(2):e0169255. PubMed ID: 28225767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation.
    Delaney WE; Locarnini S; Shaw T
    Antivir Chem Chemother; 2001 Jan; 12(1):1-35. PubMed ID: 11437320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early control of viral load by favipiravir promotes survival to Ebola virus challenge and prevents cytokine storm in non-human primates.
    Reynard S; Gloaguen E; Baillet N; Madelain V; Guedj J; Raoul H; de Lamballerie X; Mullaert J; Baize S
    PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009300. PubMed ID: 33780452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacodynamic studies (PD) of didanosine (ddI) alone and in combination with azidothymidine (AZT) in human T-cells; a stochastic biochemical approach to antiretroviral nucleoside drug combination in inhibiting HIV-reverse transcriptase (RT).
    Periclou AP; Nandy P; Avramis VI
    In Vivo; 2000; 14(3):377-88. PubMed ID: 10904870
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemically Modified Human Serum Albumin Potently Blocks Entry of Ebola Pseudoviruses and Viruslike Particles.
    Li H; Yu F; Xia S; Yu Y; Wang Q; Lv M; Wang Y; Jiang S; Lu L
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combinatorial screening of a panel of FDA-approved drugs identifies several candidates with anti-Ebola activities.
    Du X; Zuo X; Meng F; Wu F; Zhao X; Li C; Cheng G; Qin FX
    Biochem Biophys Res Commun; 2020 Feb; 522(4):862-868. PubMed ID: 31806372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clomiphene and Its Isomers Block Ebola Virus Particle Entry and Infection with Similar Potency: Potential Therapeutic Implications.
    Nelson EA; Barnes AB; Wiehle RD; Fontenot GK; Hoenen T; White JM
    Viruses; 2016 Aug; 8(8):. PubMed ID: 27490565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection.
    Marinos G; Naoumov NV; Williams R
    Hepatology; 1996 Nov; 24(5):991-5. PubMed ID: 8903365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.